IGFBP7 and acute kidney injury: Later, Beitland et al. reported an incidence of AKI of 45% in patients treated with TTM after OHCA and described a urinary [TIMP-2]·[IGFBP7] level ≥ 0.36 as an independent risk marker for AKI.